Scribe Therapeutics Inc. (NASDAQ:SCTX – Get Free Report) Director Behzad Aghazadeh purchased 7,905 shares of the firm’s stock in a transaction dated Tuesday, July 28th. The stock was acquired at an average cost of $18.25 per share, with a total value of $144,266.25. Following the completion of the acquisition, the director directly owned 3,088,888 shares in the company, valued at approximately $56,372,206. This trade represents a 0.26% increase in their position. The purchase was disclosed in a legal filing with the SEC, which is accessible through this hyperlink.
Behzad Aghazadeh also recently made the following trade(s):
- On Friday, July 24th, Behzad Aghazadeh acquired 2,383,333 shares of Scribe Therapeutics stock. The shares were acquired at an average cost of $15.15 per share, with a total value of $36,107,494.95.
Scribe Therapeutics Price Performance
NASDAQ SCTX traded down $0.91 during trading hours on Tuesday, reaching $18.06. The company’s stock had a trading volume of 428,502 shares, compared to its average volume of 423,801. Scribe Therapeutics Inc. has a 52 week low of $17.31 and a 52 week high of $25.49.
Recommended Stories
- Five stocks we like better than Scribe Therapeutics
- These 3 Stocks Have Soared in 2026—Can They Keep Climbing?
- Hasbro’s Earnings Beat Shows Why This Is No Longer Just a Toy Story
- Rambus: Another AI Phoenix Ready to Rise From the Ashes of Correction
- Chips & Clips: Memory Tariffs Rewire Tech Supply Chains
Receive News & Ratings for Scribe Therapeutics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Scribe Therapeutics and related companies with MarketBeat.com's FREE daily email newsletter.
